Subtopic Deep Dive
Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis
Research Guide
What is Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis?
Macrophage Activation Syndrome (MAS) is a life-threatening complication of systemic Juvenile Idiopathic Arthritis (sJIA) characterized by excessive macrophage and T-cell activation leading to cytokine storm and hemophagocytosis.
MAS occurs in up to 10-30% of sJIA patients and shares features with hemophagocytic lymphohistiocytosis (HLH). The 2016 MAS-HLH classification criteria enable early diagnosis using ferritin, platelets, triglycerides, and other markers (Ravelli et al., 2015, 739 citations). Cytokines like IL-1, IL-6, and IL-18 drive pathogenesis, with therapies targeting these pathways showing efficacy.
Why It Matters
MAS carries high mortality if untreated, but rapid diagnosis and IL-1 blockade improve outcomes in sJIA patients (Pascual et al., 2005). Tocilizumab targets IL-6 effectively in refractory cases (De Benedetti et al., 2012), while canakinumab reduces MAS flares (Ruperto et al., 2012). Accurate criteria from Ravelli et al. (2015) guide pediatric rheumatologists in distinguishing MAS from sJIA flares, enabling timely intervention and reducing ICU admissions.
Key Research Challenges
Distinguishing MAS from sJIA Flares
Overlapping symptoms like fever and rash complicate diagnosis without specific biomarkers. Ravelli et al. (2015) developed 2016 criteria, but ferritin thresholds vary. Jordan et al. (2011) highlight need for integrated HLH scoring in rheumatic contexts.
Cytokine Storm Mechanism Elucidation
IL-18 and IL-1 drive uncontrolled inflammation, but triggers remain unclear (Dinarello et al., 2013; Pascual et al., 2005). Balancing immune suppression risks infections. Tanaka et al. (2014) note IL-6 amplification in MAS.
Optimizing Biologic Therapies
Anakinra and canakinumab succeed, but tocilizumab risks MAS induction (De Benedetti et al., 2012; Ruperto et al., 2012). Refractory cases need combination regimens. Long-term safety data are limited.
Essential Papers
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka, Masashi Narazaki, T Kishimoto · 2014 · Cold Spring Harbor Perspectives in Biology · 4.7K citations
Interleukin 6 (IL-6), promptly and transiently produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute phase responses, hematopoiesis, a...
How I treat hemophagocytic lymphohistiocytosis
Michael B. Jordan, Carl E. Allen, Sheila Weitzman et al. · 2011 · Blood · 1.1K citations
Abstract Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of pathologic immune activation, occurring as either a familial disorder or a sporadic condition, in association with a variety of tr...
Evidence that cytokines play a role in rheumatoid arthritis
Fionula M. Brennan, Iain B. McInnes · 2008 · Journal of Clinical Investigation · 1.1K citations
A large number of cytokines are active in the joints of patients with rheumatoid arthritis (RA). It is now clear that these cytokines play a fundamental role in the processes that cause inflammatio...
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
Virginia Pascual, Florence Allantaz, Edsel Arce et al. · 2005 · The Journal of Experimental Medicine · 910 citations
Systemic onset juvenile idiopathic arthritis (SoJIA) encompasses ∼10% of cases of arthritis that begin in childhood. The disease is unique in terms of clinical manifestations, severity of joint inv...
Interleukin-18 and IL-18 Binding Protein
Charles A. Dinarello, Daniela Novick, Soohyun Kim et al. · 2013 · Frontiers in Immunology · 909 citations
Interleukin-18 (IL-18) is a member of the IL-1 family of cytokines. Similar to IL-1β, IL-18 is synthesized as an inactive precursor requiring processing by caspase-1 into an active cytokine but unl...
IL‐1, IL‐18, and IL‐33 families of cytokines
William P. Arend, Gaby Palmer, Cem Gabay · 2008 · Immunological Reviews · 887 citations
Summary: The interleukin‐1 (IL‐1), IL‐18, and IL‐33 families of cytokines are related by mechanism of origin, receptor structure, and signal transduction pathways utilized. All three cytokines are ...
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti, Hermine I. Brunner, Nicolino Ruperto et al. · 2012 · New England Journal of Medicine · 840 citations
Tocilizumab was efficacious in severe, persistent systemic JIA. Adverse events were common and included infection, neutropenia, and increased aminotransferase levels. (Funded by Hoffmann-La Roche; ...
Reading Guide
Foundational Papers
Start with Pascual et al. (2005) for IL-1 in sJIA pathogenesis, Tanaka et al. (2014) for IL-6 mechanisms (4677 citations), and Jordan et al. (2011) for HLH treatment principles applicable to MAS.
Recent Advances
Study Ravelli et al. (2015) for MAS classification criteria (739 citations), De Benedetti et al. (2012) tocilizumab trial, and Ruperto et al. (2012) canakinumab results.
Core Methods
Core methods include MAS-HLH 2016 scoring, cytokine ELISA (IL-1/6/18), flow cytometry for hemophagocytosis, and RCTs for biologics like anakinra/tocilizumab.
How PapersFlow Helps You Research Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis
Discover & Search
Research Agent uses searchPapers and exaSearch to query 'MAS-HLH 2016 criteria Ravelli' retrieving Ravelli et al. (2015) with 739 citations, then citationGraph maps connections to Jordan et al. (2011) HLH treatment guidelines and findSimilarPapers uncovers IL-18 roles in Dinarello et al. (2013).
Analyze & Verify
Analysis Agent applies readPaperContent to extract cytokine profiles from Pascual et al. (2005), verifies claims via verifyResponse (CoVe) against Tanaka et al. (2014) IL-6 data, and runPythonAnalysis computes GRADE scores for evidence strength in De Benedetti et al. (2012) tocilizumab trial, enabling statistical verification of MAS response rates.
Synthesize & Write
Synthesis Agent detects gaps in IL-18 therapies post-Dinarello et al. (2013), flags contradictions between IL-1 blockade efficacy (Pascual et al., 2005) and tocilizumab risks, while Writing Agent uses latexEditText, latexSyncCitations for Ravelli et al. (2015), and latexCompile to generate review manuscripts with exportMermaid diagrams of cytokine pathways.
Use Cases
"Analyze cytokine levels in MAS vs sJIA cohorts from recent trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas on extracted data from Pascual et al. 2005 and Ruperto et al. 2012) → matplotlib plots of IL-1/IL-18 correlations output as CSV.
"Draft LaTeX review on MAS diagnostic criteria evolution"
Synthesis Agent → gap detection on Ravelli et al. 2015 → Writing Agent → latexEditText + latexSyncCitations (Jordan 2011, De Benedetti 2012) → latexCompile → PDF with embedded tables.
"Find code for HLH scoring models linked to MAS papers"
Research Agent → citationGraph on Ravelli 2015 → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → R script for MAS-HLH calculator.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ sJIA-MAS papers starting with searchPapers on 'MAS juvenile idiopathic arthritis', chains to citationGraph for Tanaka (2014) IL-6 network, and outputs structured report with GRADE grading. DeepScan applies 7-step analysis with CoVe checkpoints to verify cytokine claims in Pascual et al. (2005). Theorizer generates hypotheses on IL-18 triggers from Dinarello et al. (2013) and Ravelli et al. (2015).
Frequently Asked Questions
What defines MAS in sJIA?
MAS is classified by 2016 criteria: ferritin >684 ng/mL, platelets ≤181x10^9/L, triglycerides >156 mg/dL, plus fever and splenomegaly or cytopenias (Ravelli et al., 2015).
What cytokines drive MAS pathogenesis?
IL-1, IL-6, and IL-18 are central; Pascual et al. (2005) show IL-1 dominance in sJIA, Tanaka et al. (2014) detail IL-6, Dinarello et al. (2013) IL-18 roles.
What are key papers on MAS treatments?
De Benedetti et al. (2012) prove tocilizumab efficacy (840 citations); Ruperto et al. (2012) validate canakinumab; Jordan et al. (2011) guide HLH protocols.
What open problems exist in MAS research?
Distinguishing MAS from infection/sJIA flares, predicting biologic-induced MAS (tocilizumab), and identifying MAS-specific biomarkers beyond ferritin remain unresolved.
Research Autoimmune and Inflammatory Disorders Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers